ClinicalTrials.gg
RecruitingNCT06324942Updated Jun 15, 2026

Analgesic Efficacy of Surgeon-administered Transversus Abdominis Plane Blocks for Caesarean Section.

An interventional study of Surgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg in Cesarean Section Complications and Pain, Postoperative, sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by University of Calgary · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 190 studies in Pain, Postoperative with a site in Canada — 38 open to participants now, 42 under way, 3 of them phase 3. Pain, Postoperative · Canada.

Planned enrollment
92nd of 175
80 · median 82
Started
2025
with 11 others
No phase
94 of 190
17 open now
Primary completion
2026-12
later than 22 of 41 live
Registered
169th of 190
by date
Lead sponsor
5 of 190
University of Calgary

Among the 190 studies in Pain, Postoperative with a site in Canada, this one is the 92nd largest by planned enrollment of the 175 interventional ones that give a count, is one of 12 that started in 2025, is one of 94 with no phase, reaches primary completion later than 22 of the 41 other live ones, and was the 169th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

38 of the 190 studies in Pain, Postoperative with a site in Canada are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Pain, Postoperative with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this research study is to evaluate whether or not adding a Transversus Abdominis Plane Block (TAP block) improves pain control for patients having a cesarean section. A TAP block is a type of nerve block where at the end of the surgery an injection of a long acting local anesthetic is made into the abdominal wall. In studies in patient's having other abdominal surgeries this has reduced the amount of narcotics patients need for pain control. This may also led to patients being more active after surgery and maybe spending less time in hospital.

Read the detailed description

Randomized clinical trial of Transversus Abdominis Plane Block (TAP block) at Cesarean Section.

03

Conditions studied

  • Cesarean Section Complications
  • Pain, Postoperative

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ASA status II to III
  • All patients undergoing elective CS under regional anesthesia at any gestational age.

Exclusion criteria

Exclusion Criteria:

  • - Known drug allergy to local anesthetics
  • Planned general anesthetic
  • NSAID use post partum
  • Chronic pain disorder or chronic narcotic use/dependence
  • Planned vertical abdominal incision
  • Planned Cesarean Hysterectomy.
  • Placenta Previa or suspected Placenta Accreta
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Surgeon-administered Transversus Abdominis Plane Block (TAP block)

    After uterine closure, the anterior abdominal wall on the contralateral side to the surgeon is elevated and retracted laterally by an assistant. The bowel and uterus is retracted using the surgeon's non-dominant hand, with or without a sponge. Under direct visualization, a blunted spinal needle is inserted lateral to the rectus muscle to avoid injury to inferior epigastric blood vessels. The needle is then gently advanced through the transversus abdominis fascia into the TAP plane, identified at loss of resistance, or 'a pop'. After aspiration to confirm no accidental placement of the needle intravascularly, local anaesthetic is infiltrated into the transverse abdominis plane through the parietal peritoneum by the surgeon at a prespecified dose of 0.25% bupivicaine 0.25 mL/kg (approximately 20cc). This is repeated on the contralateral side, after which closure of the fascia, subcutaneous tissue, and skin were performed.

    Other: Surgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg

  • No intervention
    No TAP block

    A sham procedure will not be performed but the patient will be unaware of whether or not an injection was done.

Interventions

  • OtherSurgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg

    Surgeon-administered Transversus Abdominis Plane Block

    Also known as: TAP block

06

What researchers measure

Primary outcomes

  1. Post operative Pain

    VAS scale 0-no pain to 10-worst pain

    Time frame: 12 hours post op

Secondary outcomes

  1. Time to first request for rescue analgesia in hours

    Time from completion of surgery to first request for rescue analgesia in hours

    Time frame: 48 hours post op

  2. Post operative Opioid use

    Total opioid consumption in the first 24h and 48h mark, postoperatively

    Time frame: up to 48 hours post op.

  3. Time from surgery to discharge from hospital

    Time from completion of surgery to discharge

    Time frame: Up to discharge from hospital, usually 1-3 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 22 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2024
First posted
Mar 22, 2024
StartActual
Feb 19, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06324942
Responsible party
Stephen Wood (Dr Stephen Wood, University of Calgary) — Principal investigator
First posted
Mar 22, 2024
Start date
Feb 19, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 15, 2026

Study contacts

Stephen Wood, MD
Contact
slwood@ucalgary.ca
4039441438
Stephen Wood, MD
principal investigator · University of Calgary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion